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ABSTRACT
Objective: The objective of the present work was to investigate the association between aromatase enzyme activity and polymorphisms, rs2236722, 
in exon 2 of cytochrome P450 (CYP), superfamily19, polypeptide 1 (CYP19A1gene) in patients with active acromegaly.
Methods: A total of 120 males and females (age 20-60 years) were enrolled in this study, 60 patients with active acromegaly who have attended 
the National Diabetes Centre and and Specialist Center for endocrinology and diabetes, Baghdad, from December 2015 to June 2016 and 60 healthy 
individuals with matches as a control group. From the whole blood, genomic DNA was extracted to perform genotyping analysis and single-nucleotide 
polymorphism, rs2236722, in the CYP19A1 gene using multiplex polymerase chain reaction technique, and serum aromatase levels were determined 
using a solid-phase enzyme-linked immunosorbent assay based on sandwich method.
Results: The results show that the aromatase activity levels of patients were a highly significant decrease when contrasted with healthy control 
groups in both sexes (p≤0.01), and there were summarized positive results of an allele in single-nucleotide polymorphism, rs2236722, were highly 
significant in TT allele when contrasted with healthy control groups. While revealed that there was non-significant difference in TC allele when 
contrasted with healthy control groups (p>0.01).
Conclusion: we conclude that there was associated between CYP19A1 gene polymorphism (rs2236722) with aromatase activity and related to 
acromegaly patients.
Keywords: Aromatase activity, Single-nucleotide polymorphism, rs2236722, Active acromegaly.
INTRODUCTION
Acromegaly is an uncommon hormonal condition that develops most 
commonly from benign somatotroph pituitary adenomas; the clinical 
indications connected with acromegaly are a result of the chronic 
overproduction of growth hormone (GH) and insulin-like growth 
factor 1 [1,2]. Systemic complications usually connected with the chronic 
hypersecretion of GH and insulin-like growth factor 1 (IGF-1) include 
acromegaly, soft tissue changes, and arthralgia, and comorbidities 
include type 2 diabetes, hypertension, carpal tunnel syndrome, and 
sleep apnea [3]. The aromatase cytochrome P450 (CYP) is vital for the 
biosynthesis of estrogens in few tissues, in particular, the ovary, adipose 
tissue, and brain [4]. By standards of other CYP genes that encoding the 
aromatase (CYP19) is extraordinarily significant since it is more than 
50 kbp at chromosome 15q21.2. CYP, superfamily19, polypeptide 1 
(CYP19A1) is situated and extends about (123 kb) in length. It 
contains 9 coding exons and various untranslated first exons whose 
expression is regulated by tissue-specific promoters [5,6]. In a wide 
assortment of tissues, aromatase is expressed and it has been found in 
the brain, placenta, liver, ovary, skin, testis, and adipose tissue [7]. At 
the transcriptional levels in the brain, placenta, and gonads, the tissue-
specific promoters regulate the aromatase gene [8]. The protein result 
of aromatase gene has so far been found the same despite of the tissue-
specific expression patterns of aromatase. The control aromatase gene 
expression at all levels: mRNA, protein, functional, and enzymatic 
activity has been considered as important not only for the treatment 
of breast cancer but also the critical role of aromatase enzyme [9], 
but as well in males, for example, in the cases of prostate cancers or 
gynecomastia [10]. In every pituitary tissue, there was an expression of 
aromatase enzyme inclusive autopsy samples and were most increased 
in patients with acromegaly than in another adenoma groups. In 
patients with functional adenoma, aromatase expression was elevated 
in patients with than without post-operative complete remission. 
These results suggest that aromatase expression perhaps a useful 
prognostic marker of pituitary adenomas [11]. Previous studies are 
examining the associations of selected CYP19A1 variants, such as the 
polymorphisms in intron 4 and the non-synonymous polymorphisms 
Trp39Arg (rs2236722) in exon 2 [12]. The aim of this research was to 
estimate the activity of aromatase in acromegaly patients and compare 
with a control group and study the genetic polymorphism (rs2236722) 
for aromatase enzyme (CYP19A1) gene and determine the relation 
between aromatase activity and the polymorphism of gene CYP19A1.
PATIENTS AND METHODS
A total of 120 males and females (age 20-60 years) were enrolled in 
this study, 60 patients with active acromegaly who have attended the 
National Diabetes Centre and Specialist Center for endocrinology and 
diabetes, Baghdad, from December 2015 to June 2016 and 60 healthy 
individuals with matches as a control group. Physicians diagnosed 
all patients, and the study was approved by the Center Ethical 
Committee. Blood was collected, each blood sample was split into 
two fractions. The first fraction was conveyed into a tube containing 
ethylenediaminetetraacetic acid (EDTA) disodium salt for whole blood 
for genotyping analysis. The other fraction was separated in plain 
polyethylene test tube, left to clot at room temperature, then the tube 
was centrifuged at 704 ×g for 10 minutes, and the sera were separated.
Determination of serum aromatase activity
Serum aromatase levels were determined using human aromatase kit 
using a solid-phase enzyme-linked immunosorbent assay based on 
sandwich method; at a wavelength of 450±2 nm, the optical density 
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is measured by spectrophotometric. The optical density value is 
proportional to aromatase concentration and then calculated the 
aromatase concentration in serums by comparing the optical density in 
the serums to the standard curve.
DNA extraction
The blood samples are collected in EDTA tubes from patient and healthy 
control groups. The genomic DNA is extracted from the whole blood by 
G-SpinTM total DNA extraction kit.
Detection of rs2236722 gene using multiplex polymerase chain 
reaction (multiplex PCR)
Achievement of optimization of PCR reactions was after several endeavors 
to detect the best annealing temperature and the concentrations of 
both DNA and primer. Briefly, amplified the genomic DNA by two pairs 
of primers, forward primer (1/F: 5′- ATCTGTACTGTACAGCACC-3′) 
and reverse primer (1/R: 5′- ATGTGCCCTCATAATTCCG -3′), for the C 
allele, and a forward primer (2/F: 5′-GGCCTTTTTCTCTT GGTGT-3′) 
and a reverse primer (2/R: 5′-CTCCAAGTCCTCATTTGCT-3′), for the T 
allele (primers set supplied by the IDT (Integrated DNA Technologies 
company, Canada). PCR reaction was conducted in 25 µl of a reaction 
mixture containing 1.5 µl (50-100 ng) of DNA, 5 µl of PreMix Master 
Mix, 0.5 µl of (10 Pmol\µl) of each primer, and 16.5 µl of distilled water. 
Amplification program was one cycle at 94°C for 3 minutes; 35 cycles at 
94°C for 45 seconds, 58°C for 45 seconds, and 72°C for 45 seconds; and 
one cycle at 72°C for 10 minutes; the amplified product was subjected 
to 2% agarose gel electrophoresis with 1.0 µl of red stain dye and 5 µl 
ladder and visualized under UV (Agarose Gel Electrophoresis System 
MGu-502T-pk, USA) after red-safe staining.
Statistical analysis
1. Statistical analysis was performed by utilizing the Microsoft Office 
(SPSS vs. 19) which includes the following mean± standard deviation 
test, correlation coefficient, and p≤0.01 was statistically significant. 
In all studied groups, the total prescient values for the outcomes 
were performed according to Biostatistics through Daniel in 1987.
2. The statistical analysis system was utilized. The Pearson x2 criterion 
(p≤0.01), 95% confidence intervals (CI), and odds ratio (OR) tests 
were employed to compare the polymorphisms of frequencies of 
CYP19A1 gene between the groups.
RESULTS
Serum aromatase activity level indices in studied groups
Table 1 showed the mean±SD of aromatase activity levels expressed 
as ng/ml in serum of 60 healthy individuals (males and females) and 
60 active acromegaly patients (males and females). These results 
showed that there was a highly significant decrease in aromatase 
activity levels of male and female acromegaly when contrasted with the 
control group in both sexes (p≤0.01).
Genotyping analysis of rs2236722 polymorphisms
This study includes extracting DNA from the blood of 60 female and 
male healthy individuals and 60 female and male patients. Agarose 
gel electrophoresis checked the quality and integrity of DNA before 
doing PCR. Genotyped the CYP19A1 rs2236722 single-nucleotide 
polymorphism (SNP) with a PCR method using two-pair primers. 
Briefly, 25 nanograms of DNA was utilized for each PCR reaction. Some 
samples were repeated twice to confirm PCR result. Further subjected 
the PCR products to 2% agarose gel electrophoresis and identified the 
alleles as follows: The T allele was represented by DNA bands with 
sizes 427 bp; the TC allele was represented by DNA bands with sizes 
(427, 264, and 200 bp) as shown in Fig. 1.
Table 2 summarizes the positive results of allele of multiplex in male and 
female of sample study (patients and controls). 10 male patients from 
30 male patients with the present TT allele (52.63%) and no current with 
male control. These results showed that there was a highly significant 
in TT allele when compared with male control group. While 20 male 
patients from 30 male patients with present TC allele (48.78%) and all 
30 male controls with present TC allele (50.00%), these results showed 
that there was non-significant difference in TC allele when contrasted 
with a male control healthy group (p≥0.01). Moreover, 9 female patients 
from 30 female patients with present TT allele (47.37%) and no current 
with female controls. These results showed that there was a highly 
significant in TT allele when compared with female control group. 
While 21 female patients from 30 female patients with present TC allele 
(51.22%) and all 30 female controls with present TC allele (50.00%), 
these results showed that there was non-significant difference in TC 
allele when contrasted with female control healthy group (p≥0.01). The 
CC allele not presents in all patient and control groups in both sexes.
Allele frequency
Table 3 summarizes the frequency distribution genotypes of CYP19A1 
rs2236722 T<C polymorphism and allele frequency in patient and 
Table 1: Serum aromatase activity levels in studied groups




M 11.209±0.364 2.836±1.095 −34.807 0.000*
F 23.293±0.003 2.774±1.638 −51.648 0.000*
*The t-test insignificant at the 0.01 level or less, M: Male, F: Female, 
SD: Standard deviation
Table 2: Results of multiplex in male and female of sample study (patients and controls)
The group Sum of positive results of 
allele TT (200, 427) (%)
p value Sum of positive results of 
allele CC (264, 427) (%)
p value Sum of positive results of 
allele TC (200, 264, 427) (%)
p value
Male Female Male Female Male Female
Patients 10 (52.63) 9 (47.37) 0.328 NS 0 (0.00) 0 (0.00) 1.00 NS 20 (48.78) 21 (51.22) 0.573 NS
Controls 0 (0.00) 0 (0.00) 1.00 NS 0 (0.00) 0 (0.00) 1.00 NS 30 (50.00) 30 (50.00) 1.00 NS
p value 0.0001** 0.0001** - 1.00 NS 1.00 NS --- 0.804 NS 0.804 NS
**p<0.01, NS: Non-significant
Fig. 1: Genotyping of cytochrome P450, superfamily19, 
polypeptide 1 rs2236722 T<C polymorphisms by multiplex 
polymerase chain reaction in control and patient samples, Lane 
M, 500 bp DNA ladder, lanes 1-9, TT genotype (427 and 200 bp), 
and lanes 10-13, TC genotype (427, 264, and 200 bp)
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control groups for both sexes. 60 healthy individuals (100%) of total 
participants were used in this study and had present rs2236722 T<C 
polymorphism amplification, whereas the distribution of genotype TC 
was (60) 100%, and 60 patients (100%) had present rs2236722 T<C 
polymorphism amplification, whereas the distribution of genotype TT 
was (19) 31.67% and the distribution of genotype TC was (41) 68.33%. 
The frequency of homozygote T allele in the present study of patients 
was 0.66, which was higher than the frequency of homozygote T allele 
of control was 0.50, while the frequency of heterozygote C allele in the 
present study of patients was 0.34, which was lower than the frequency 
of heterozygote C allele of control was 0.50.
To measure 95% CI and OR for acromegaly risk, different comparisons 
of rs2236722 alleles additionally analyzed C versus T alleles as 
shown in Table 4. The particular acromegaly subpopulations’ OR 
for CC versus TT and TC versus TT alleles additionally CC versus 
TC alleles was estimated. The patients with acromegaly OR for CC 
versus TT and TC versus TT patients was 1.28 (0.96-1.61, 95% CI). 
Hence, in this group, the TT allele tended to be correlated with an 
elevated acromegaly risk as indicated through OR >1, although these 
differences were significant, while the OR for healthy control for TT 
versus TC and CC versus TC individuals was 2.00 (0.96-1.61, 95% 
CI). Hence, in this group, the TC allele tended to be correlated with a 
decreased acromegaly risk as indicated through OR >1, the differences 
were significant.
Correlation between genotypes and aromatase activity
This research concludes to the aromatase enzyme activity measurement 
in serum for acromegaly patients and healthy controls and compares the 
results to their alleles. The results detected in aromatase activity were 
a significant decrease (p≤0.01) in acromegaly relation to the control 
group. Table 5 shows that the activity of aromatase was a significant 
decrease (p≤0.05) in patients carrying TC allele of both rs10046 and 
rs2236722 contrasted to individual that had the same alleles in healthy 
control group. While between the two groups, the activity of other 
alleles did not seen any significant.
DISCUSSION
This is the first study in the world that investigated the correlation of 
CYP19A1 gene polymorphisms with the acromegaly. We accurately 
limited the study people to the Iraqi people in the areas of Baghdad 
city to keep up genetic homogeneity between the people furthermore 
to avert the confusing effects of environmental factors and interracial 
differences of genetic backgrounds, such as living behaviors. The 
current study investigates the aromatase activity and polymorphism of 
CYP19A1 genes among 60 apparently healthy and 60 active acromegaly 
patients from different regions of Baghdad metropolis; the association 
among the CYP19A1 gene polymorphisms and various factors was 
studied. Then, the CYP19 polymorphism sites were chosen in public 
databases (http://www.ncbi.nlm.nih.gov/snp/). Our research was 
shown that there was associated between CYP19 gene polymorphism 
(rs2236722) with aromatase activity and related to acromegaly 
in Iraqi patients. We found there was the statistically significant 
correlation between the aromatase enzyme activity and the existence 
of the allele, that’s mean the decrease of aromatase enzyme activity 
demonstrates lead to increased presence of an allele or that allele is 
satisfactory allele and the individual has acromegaly disease, also we 
can distinguish between of patients and healthy samples especially 
when the appearance of TC allele by measuring the activity of the 
enzyme, therefore, can diagnosis the disease. In this comprehension 
in human biology, the role of aromatase has been promoted through 
a few individual situation statements of the patients with complete 
aromatase deficiency [13]. The previous studies like Lin et al. explain 
that aromatase mutations can make in humans variable or “non-
classic” phenotypes. At puberty, little residual aromatase activity may 
be adequate for the breast and uterine development to occur, in spite 
of important androgenization in utero. That phenotypic variability 
may be affected further by modifying factors such as variability in 
coregulators, non-classic pathways of estrogen synthesis, or differences 
in androgen responsiveness propose an important modulatory function 
for this enzyme in metabolic function and endocrine within the broader 
population [14].
Based on our previous assessment, our analysis in this study evaluated 
whether inter-individual variation in the CYP19A1 gene alters 
susceptibility to acromegaly conditions in Iraqi patients. The overall 
risk of either disease outcome was related to the individual genotypes 
since the risk of acromegaly associated with several gene variants 
differed according to proliferation status. While another study by Ledan 
et al. shows that the variation in the CYP19A1 gene alters capability 
to fibrocystic breast or breast cancer conditions in Chinese women. 
In our study, our analysis revealed a significant association between 
polymorphism rs2236722 and acromegaly related to a deficiency in 
aromatase activity. In agreement with this suggestion, breast cancer, 
infertility, and endometriosis studies have found that patients related 
with this polymorphism. The overall risk of either disease outcome 
was not related to any of the individual genotypes or block-specific 
haplotypes although the risk of breast cancer correlated with several 
gene variants differed according to proliferation status. The observed 
Table 3: Distribution of gene polymorphism and allele 
frequency in patients and controls
Genotype n (%)
Patients Healthy
TT 19 (31.67) 0 (0.00)
TC 41 (68.33) 60 (100)
CC 0 (0.00) 0 (0.00)
Total 60 (100) 60 (100)




Total 1 (100) 1 (100)
**p<0.01
Table 4: OR, P values, and 95% confidence intervals for the correlated with CYP19A1 (rs2236722 ) alleles with acromegaly risk
Allele Number of patients (%) Compared genotypes OR 95% CI
TC 41 (68.33) CC vs. TT 1.28 (0.96-1.61)
TT 19 (31.67) TC vs. TT 1.28 (0.96-1.61)
CC 0 (0.00) CC vs. TC 1.63 (0.93-1.61)
Chi-square value (χ2) 8.923**
Allele Number of healthy (%) Compared genotypes OR 95% CI
TT 0 (0.00) TT vs. TC 2.00 (0.96-1.61)
CC 0 (0.00) CC vs. TC 2.00 (0.96-1.61)
TC 60 (100) CC vs. TT 0.00 (0.96-1.61)
Chi-square value (χ2) 15.00**
OR: Odds ratios, CYP19A1: cytochrome P450, superfamily19, polypeptide 1, CI: Confidence intervals, **: p<0.01
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increases in risk among breast cancer cases with, but not without, 
synchronous proliferative fibrocystic status indicate that CYP19A1 
variation may only influence breast cancer etiology in this particular 
subgroup of women [15]. Moreover, another study by Chen et al. (2008) 
found that the elevated hazard of breast cancer with proliferative 
fibrocystic status about individual CYP19A1 markers was pronounced 
among women who were post-menopausal or had a BMI ≥23 kg/m2. 
They observed could be explained by chance due to the number of 
analyses conducted and comparisons made; there are data to suggest 
that the chromosomal region 15q21.1, where CYP19A1 is located, may 
influence breast cancer progression [12]; likewise, the other studies 
by Kristensen et al. showed that the examined CYP19 polymorphisms 
(rs700518: A>G,rs2236722: T>C, [TTTA]n repeat, and rs10046: T>C) 
were not significantly correlated with the hazard of infertility and 
endometriosis or endometriosis with ovarian chocolate cysts in Chinese 
women [16]. Many prior studies from Korean people [17], Japanese 
people [18], and Caucasian people [19], all of that showed no significant 
correlation of CYP19 gene polymorphisms with the hazard of chocolate 
cysts or endometriosis. The study by Hirose et al., [20] showed that in 
estrogen biosynthesis, the genetic polymorphisms (CYP19A1) are as 
well expected to affect the degradation or synthesis of estrogen, and 
then, lead to increase the breast cancer risk at codon 39 [21,22], the 
(rs2236722) polymorphism is created by the substitution of amino 
acids (Trp) with (Arg), while another study showed the Japanese 
women with the presence of these different alleles (Arg) lead to 
significantly decreased the developing of the breast cancer risk [23]. 
In a survey by Leporati et al., the authors deal with the male patients 
with breast cancer and acromegaly. The breast cancer clinical course 
was closely concerning to the metabolic monitoring of acromegaly. 
The rapid metastatic lesion progression was temporally concerning 
to stopping treatment by pegvisomant and paralleled an increasing 
in serum levels of IGF-1. Normalization of serum IGF-1 levels after 
restarting pegvisomant impressively decreased the metastatic breast 
lesions progression. Acromegaly control is compulsory in acromegalic 
patients with cancer and evaluated the function of AIP mutations, which 
occur in pituitary adenomas, in the common genesis types of cancer 
(breast, prostate, and colorectal cancer) [24]. The studies by Surekha 
et al. showed that the aromatase gene expression is regulated in a 
tissue promoter I.4 governs particular manner and in adipose tissue 
expression [25], while Belgorosky et al. suggested that the lower of 
aromatase activity leads to the degree of masculinization of the external 
genitalia was greater at birth in females that exposure to an excess 
of androgens resulted in a changeable virilization of the mother and 
masculinization of the external genitalia since about 1% of the activity 
of placental aromatase of wild-type aromatase enzyme appears to be 
enough to prevent the mother virilization during pregnancy. Moreover, 
the absence of estrogen synthesis because of complete aromatase 
activity deficiency resulted in increased concentration of essential 
FSH [26,27]. Based on previous results, we in our analysis expand and 
refine previous results (including our own) by identifying a number of 
variables that predict and expected the present deficits in function of 
aromatase activity in those patients. In the current work, we suggested 
that once this correlation is confirmed by the biological importance of 
aromatase enzyme and illustrated through functional studies and this 
polymorphism could be a probable target for the early treatment and 
prevention of acromegaly.
CONCLUSION
This is the first study in the world investigating  to found the 
correlation  between of CYP19A1 gene polymorphisms and aromatase 
enzyme activity in the acromegaly disease. Proved the TT and TC 
genotypes tended to be correlated with an increased acromegaly 
risk where the relationship between rs2236722 SNP and aromatase 
enzyme  activity was as following, whenever found the TT  or TC 
genotypes and deficiency in aromatase enzyme activity that means 
there was active acromegaly disease, while in  healthy  individuals 
found the TC genotype   but with normal enzyme activity, therefore, 
we can distinguish between of patients and healthy  individuals and 
diagnosis the disease.
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